Literature DB >> 18291260

Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience.

Gennaro Nuzzo1, Felice Giuliante, Francesco Ardito, Maria Vellone, Ivo Giovannini, Bruno Federico, Fabio M Vecchio.   

Abstract

BACKGROUND: Hepatectomy for colorectal liver metastases (CRLM) may offer good long-term survival. The impact of the tumor-free surgical margin on long-term results remains controversial, and we have assessed this component in 185 patients.
METHODS: Between 1992 and 2005, 185 patients underwent primary hepatectomy with curative intent for CRLM (which originated from colon/rectum 133/52, synchronous/metachronous 66/119, and single/multiple 100/85). In this study, 105 major and 80 minor hepatectomies were evaluated; 133 hepatectomies had pedicle clamping.
RESULTS: Operative mortality was 1.1%, morbidity was 25.7%, and blood transfusion requirement was 27.6%. Stratification of tumor-free margin in the patients with R0 liver resection was greater than or equal to 10 mm (63.0% of patients), 6-9 mm (11.4% of patients), 3-5 mm (16.5% of patients), and less than or equal to 2 mm (9.1% of patients), with infiltrated margin in the remainder (R1 liver resection 4.9% of the total number of patients). The 3-year, 5-year, and 10-year survival rates were 54.9%, 37.9%, and 22.9%, respectively. Global and surgical margin recurrence rates increased as the tumor-free margin decreased (P = .01 and P < .001, respectively). At univariate analysis, the width of surgical margin (P < .001), transfusion requirement, major hepatectomy, R1 resection, number of metastases, high preoperative CEA, and increasing tumor size (P value from .001 to .03) were associated with lesser rates of long-term survival. A similar association was found with disease-free survival. At multivariate analysis, width of surgical margin was the only independent predictor of both overall (P = .003) and disease-free (P < .001) survival. Although smaller margins were associated with synchronicity, increasing number of, and with bilobar distribution of, metastases which contributed to explain recurrences away from the margin), the width of surgical margin maintained the prominent impact on outcome.
CONCLUSIONS: In our patients, the width of the surgical margin was a powerful prognostic factor after hepatectomy for CRLM. A resection margin less than or equal to 5 mm was associated with a greater risk of recurrence on the surgical margin, with a lesser rate of overall and disease-free survival.

Entities:  

Mesh:

Year:  2007        PMID: 18291260     DOI: 10.1016/j.surg.2007.09.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  51 in total

Review 1.  Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome.

Authors:  George A Poultsides; Richard D Schulick; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

2.  Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Authors:  Federico Tomassini; Italo Bonadio; Peter Smeets; Karen De Paepe; Giammauro Berardi; Liesbeth Ferdinande; Stéphanie Laurent; Louis J Libbrecht; Karen Geboes; Roberto I Troisi
Journal:  Langenbecks Arch Surg       Date:  2015-08-12       Impact factor: 3.445

3.  Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors.

Authors:  Baki Topal; Joyce Tiek; Steffen Fieuws; Raymond Aerts; Eric Van Cutsem; Tania Roskams; Hans Prenen
Journal:  Surg Endosc       Date:  2012-02-07       Impact factor: 4.584

Review 4.  Robotic Surgery for Malignant Liver Disease: a Systematic Review of Oncological and Surgical Outcomes.

Authors:  Rafael Diaz-Nieto; Soumil Vyas; Dinesh Sharma; Hassan Malik; Stephen Fenwick; Graeme Poston
Journal:  Indian J Surg Oncol       Date:  2019-06-13

5.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2019-05-02       Impact factor: 6.113

6.  Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival.

Authors:  Francesco Ardito; Maria Vellone; Alessandra Cassano; Agostino M De Rose; Carmelo Pozzo; Alessandro Coppola; Bruno Federico; Ivo Giovannini; Carlo Barone; Gennaro Nuzzo; Felice Giuliante
Journal:  J Gastrointest Surg       Date:  2012-12-08       Impact factor: 3.452

7.  Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections.

Authors:  Clarisse Eveno; Mehdi Karoui; Etienne Gayat; Alain Luciani; Marie-Luce Auriault; Michael D Kluger; Isabelle Baumgaertner; Laurence Baranes; Alexis Laurent; Claude Tayar; Daniel Azoulay; Daniel Cherqui
Journal:  HPB (Oxford)       Date:  2012-10-22       Impact factor: 3.647

8.  Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.

Authors:  Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Paxton V Dickson; Giuseppe Zimmitti; Dipen M Maru; Scott Kopetz; Evelyne M Loyer; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

9.  Aggressive surgical resection for concomitant liver and lung metastasis in colorectal cancer.

Authors:  Sung Hwan Lee; Sung Hyun Kim; Jin Hong Lim; Sung Hoon Kim; Jin Gu Lee; Dae Joon Kim; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2016-08-29

10.  Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis.

Authors:  Michihiro Hayashi; Yoshihiro Inoue; Koji Komeda; Tetsunosuke Shimizu; Mitsuhiro Asakuma; Fumitoshi Hirokawa; Yoshiharu Miyamoto; Junji Okuda; Atsushi Takeshita; Yuro Shibayama; Nobuhiko Tanigawa
Journal:  BMC Surg       Date:  2010-09-27       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.